Oral Cancer Patient Outcomes After Adjuvant Radiotherapy and PD-1 Inhibitors

262 high-risk oral cancer patients from a single-center retrospective study at The First Affiliated Hospital of Nanchang University, spanning from January 2013 to December 2024. The data compares overall survival and adverse events between patients receiving sequential PD-1 inhibitors after adjuvant radiotherapy and a control group. Author Shaoqing Chen published the study on figshare in May 2026.

Use Cases

• Compare overall survival rates based on treatment regimen.
• Analyze adverse event profiles associated with PD-1 inhibitor therapy.
• Validate propensity score matching methodologies for retrospective cohort studies.
• Study the relationship between specific adverse reactions (e.g., gastrointestinal, myelosuppression) and immunotherapy.

Strengths

• 262 patient records with a defined time range from 2013 to 2024.
• Uses propensity score matching (1:1) to create balanced cohorts of 89 patients per group.
• Reports specific hazard ratios (HR 0.54) and median overall survival (55.0 months for control group).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the matched analysis is known (89 per group), but the full dataset structure is unspecified.
• Data is from a single center, which may limit generalizability.

Provenance

Source

The First Affiliated Hospital of Nanchang University

Collection Method

Single-center, retrospective cohort study using propensity score matching.

Time Range

January 2013 to December 2024

Freshness

Last updated 2026-05-14 04:25:36; freshness should be verified.

Geography

Nanchang, China (inferred from hospital location)